Customs and Border Protection has partnered with the Food and Drug Administration to expand the focus of the Global Business Identifier test.
The expanded test will explore how the FDA and CPB can use identifiers, numbers that capture information on business entities, to address supply chain traceability, according to a news release.
“This could enhance predictability, lower costs and create the opportunity for additional facilitation benefits for compliant trade,” Troy Miller, senior official performing the duties of the Commissioner, said in the release release.
CPB said it will also assess the functionality and effectiveness of identifiers to address data gaps in its Manufacturing/Shipper Identifier requirement.
“Traceability is key to the FDA’s mission,” Dan Solis, FDA assistant commissioner for import operations, said in the release. “It enables us to leverage verifiable information at the supply chain level to identify risk and make admissibility decisions — ensuring the food, medicine and other FDA-regulated goods entering the United States are safe and get to those who need them as quickly as possible.”
CPB said it plans to modify the Global Business Identifier test, including extending it for three more years and removing commodity and country of origin limitations on the types of entries evaluated under the test.
